Literature DB >> 29770902

High isolation rate and multidrug resistance tendency of penicillin-susceptible group B Streptococcus with reduced ceftibuten susceptibility in Japan.

Hirotsugu Banno1, Kouji Kimura2, Tomomi Seki1, Wanchun Jin1, Jun-Ichi Wachino1, Keiko Yamada1, Noriyuki Nagano3, Yoshichika Arakawa1.   

Abstract

Group B Streptococcus (GBS) clinical isolates with reduced penicillin susceptibility (PRGBS) have emerged through acquisition of amino acid substitutions in penicillin-binding protein 2X (PBP2X). Moreover, we also reported the emergence of penicillin-susceptible GBS clinical isolates with reduced ceftibuten susceptibility (CTBr PSGBS) due to amino acid substitutions in PBPs. However, whether or not these amino acid substitutions are responsible for the reduced ceftibuten susceptibility (RCTBS) profile remains unclear. Furthermore, the rate of CTBr PSGBS isolation and their multidrug resistance tendency remain uncertain. Therefore, we collected 377 clinical GBS isolates from multiple regions in Japan between August 2013 and August 2015. These isolates were characterized by determining MICs and sequencing the pbp2x gene. The isolation rate of CTBr PSGBS was 7.2% (27/377). CTBr PSGBS isolate harbor two types of amino acid substitutions in PBP2X [(T394A type) and (I377V, G398A, Q412L, and H438H type)]. The relevance of the amino acid substitutions found to the RCTBS was confirmed with allelic exchange techniques. Allelic exchange recombinant clones acquired two types of amino acid substitutions in PBP2X showed RCTBS. Furthermore, total ratio of resistance and non-susceptibility to both macrolides and fluoroquinolones in CTBr PSGBS was 51.9% (14/27). The isolation rate of CTBr PSGBS is non-negligibly high and the CTBr PSGBS tends to exhibit resistance and non-susceptible profile to both macrolides and fluoroquinolones.

Entities:  

Keywords:  Group B Streptococcus; Multidrug resistance; Penicillin-binding protein 2X; Reduced ceftibuten susceptibility

Mesh:

Substances:

Year:  2018        PMID: 29770902     DOI: 10.1007/s10096-018-3278-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Group B streptococcal disease in UK and Irish infants younger than 90 days.

Authors:  Paul T Heath; Gail Balfour; Abbie M Weisner; Androulla Efstratiou; Theresa L Lamagni; Helen Tighe; Liam A F O'Connell; Mary Cafferkey; Neville Q Verlander; Angus Nicoll; A Christine McCartney
Journal:  Lancet       Date:  2004-01-24       Impact factor: 79.321

2.  Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone.

Authors:  Christiane Gaudreau; René Lecours; Johanne Ismaïl; Simon Gagnon; Louise Jetté; Michel Roger
Journal:  J Antimicrob Chemother       Date:  2009-12-18       Impact factor: 5.790

3.  Molecular Characteristics of Group B Streptococci Isolated from Adults with Invasive Infections in Japan.

Authors:  Miyuki Morozumi; Takeaki Wajima; Misako Takata; Satoshi Iwata; Kimiko Ubukata
Journal:  J Clin Microbiol       Date:  2016-08-24       Impact factor: 5.948

4.  Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA.

Authors:  B J Metcalf; S Chochua; R E Gertz; P A Hawkins; J Ricaldi; Z Li; H Walker; T Tran; J Rivers; S Mathis; D Jackson; A Glennen; R Lynfield; L McGee; B Beall
Journal:  Clin Microbiol Infect       Date:  2017-02-28       Impact factor: 8.067

5.  High isolation rate of MDR group B streptococci with reduced penicillin susceptibility in Japan.

Authors:  Tomomi Seki; Kouji Kimura; Megan E Reid; Akira Miyazaki; Hirotsugu Banno; Wanchun Jin; Jun-ichi Wachino; Keiko Yamada; Yoshichika Arakawa
Journal:  J Antimicrob Chemother       Date:  2015-07-13       Impact factor: 5.790

Review 6.  Group B streptococcus.

Authors:  A Schuchat
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

7.  Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics.

Authors:  Samira Dahesh; Mary E Hensler; Nina M Van Sorge; Robert E Gertz; Stephanie Schrag; Victor Nizet; Bernard W Beall
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

8.  Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.

Authors:  Somay Yamagata Murayama; Chizuko Seki; Hiroshi Sakata; Katsuhiko Sunaoshi; Eiichi Nakayama; Satoshi Iwata; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

Review 9.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

10.  A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults.

Authors:  M M Farley; R C Harvey; T Stull; J D Smith; A Schuchat; J D Wenger; D S Stephens
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

View more
  4 in total

1.  A Single Amino Acid Replacement in Penicillin-Binding Protein 2X in Streptococcus pyogenes Significantly Increases Fitness on Subtherapeutic Benzylpenicillin Treatment in a Mouse Model of Necrotizing Myositis.

Authors:  Randall J Olsen; Luchang Zhu; James M Musser
Journal:  Am J Pathol       Date:  2020-05-11       Impact factor: 4.307

2.  Reduced In Vitro Susceptibility of Streptococcus pyogenes to β-Lactam Antibiotics Associated with Mutations in the pbp2x Gene Is Geographically Widespread.

Authors:  James M Musser; Stephen B Beres; Luchang Zhu; Randall J Olsen; Jaana Vuopio; Hanne-Leena Hyyryläinen; Kirsi Gröndahl-Yli-Hannuksela; Karl G Kristinsson; Jessica Darenberg; Birgitta Henriques-Normark; Steen Hoffmann; Dominque A Caugant; Andrew J Smith; Diane S J Lindsay; David M Boragine; Timothy Palzkill
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

3.  Clinical and bacterial features of Group B streptococci with reduced penicillin susceptibility from respiratory specimens: a case-control study.

Authors:  Naoya Nishiyama; Takeshi Kinjo; Kohei Uechi; Gretchen Parrott; Masashi Nakamatsu; Masao Tateyama; Jiro Fujita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-12       Impact factor: 3.267

4.  Heterogeneity of penicillin-non-susceptible group B streptococci isolated from a single patient in Germany.

Authors:  Mark van der Linden; Rafael Mamede; Natascha Levina; Peter Helwig; Pedro Vila-Cerqueira; João André Carriço; José Melo-Cristino; Mário Ramirez; Elisabete R Martins
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.